Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice.
about
Recombinant TgHSP70 Immunization Protects against Toxoplasma gondii Brain Cyst Formation by Enhancing Inducible Nitric Oxide Expression.Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.Use of dense granule antigen GRA6 in an immunoglobulin G avidity test to exclude acute Toxoplasma gondii infection during pregnancy.Advances in the study of HLA-restricted epitope vaccines.Partial protective effect of intranasal immunization with recombinant Toxoplasma gondii rhoptry protein 17 against toxoplasmosis in miceTowards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201Toxoplasma gondii protein disulfide isomerase (TgPDI) is a novel vaccine candidate against toxoplasmosisDNA prime and peptide boost immunization protocol encoding the Toxoplasma gondii GRA4 induces strong protective immunity in BALB/c miceIntranasal immunisation with recombinant Toxoplasma gondii actin partly protects mice against toxoplasmosis.Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 miceVaccination with Toxoplasma gondii calcium-dependent protein kinase 6 and rhoptry protein 18 encapsulated in poly(lactide-co-glycolide) microspheres induces long-term protective immunity in mice.Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondiiToxoplasma gondii antigens recognized by IgG antibodies differ between mice with and without active proliferation of tachyzoites in the brain during the chronic stage of infection.Evaluation of Immunoprotection Conferred by the Subunit Vaccines of GRA2 and GRA5 against Acute Toxoplasmosis in BALB/c Mice.Induction of Protective Immunity against Toxoplasmosis in BALB/c Mice Vaccinated with Toxoplasma gondii Rhoptry-1.Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.GRA2 and ROP1 recombinant antigens as potential markers for detection of Toxoplasma gondii-specific immunoglobulin G in humans with acute toxoplasmosis.Protective effect of DNA-mediated immunization with liposome-encapsulated GRA4 against infection of Toxoplasma gondiiIdentifying Novel B Cell Epitopes within Toxoplasma gondii GRA6Vaccines against Toxoplasma gondii: challenges and opportunities.Current status of toxoplasmosis vaccine development.Towards a Preventive Strategy for Toxoplasmosis: Current Trends, Challenges, and Future Perspectives for Vaccine Development.Immunization of C57BL/6 Mice with GRA2 Combined with MPL Conferred Partial Immune Protection against Toxoplasma gondiiDetermination of a Key Antigen for Immunological Intervention To Target the Latent Stage of Toxoplasma gondii.Recombinant ROP2, ROP4, GRA4 and SAG1 antigen-cocktails as possible tools for immunoprophylaxis of toxoplasmosis: what's next?Evaluation of the immune response in BALB/c mice induced by a novel DNA vaccine expressing GRA14 against Toxoplasma gondii.Discovery of new Toxoplasma gondii antigenic proteins using a high throughput protein microarray approach screening sera of murine model infected orally with oocysts and tissue cysts.
P2860
Q33599823-375BBDF0-EE9F-4566-B6E5-D5D595105B09Q33956199-EC154F6E-AB36-42B4-A8B2-A2FE9E78AA70Q34150450-9E241DF2-CB60-4035-ABB8-B8E80B18C54FQ34170130-DFA848F3-5258-4B70-8798-1884FA7D8767Q34257517-EB3DAAEE-12DA-4C24-A349-E9E25ED5A8D1Q34458916-FB8106D8-649A-403F-ACAA-7E8A36439AD0Q34963118-728CF370-C892-4087-B313-523ED406EBE3Q35023899-E210C927-CF61-42C4-9F96-BDDCD02161F3Q35080048-4D1FDAF3-3C9A-4DDD-A9DA-B14D71FA1289Q35634197-D9D2A04A-F063-4944-97D8-AF837EB6C2D1Q35993075-71CBC025-4BFA-4AE0-BF09-94634BAC9891Q36240866-FB7AD81E-D2CE-4FD1-9214-BC12630B9AFFQ36277374-E077FC92-9DC1-45DF-B818-37BEA2120B9EQ36843269-56323540-2A1B-4B05-9E2B-1E4DF8A2A0B5Q36943560-9921005B-C0D1-41B9-B5AB-B64E6ABEC702Q37109519-45AC07FE-3E40-4450-872D-48E62CCB4080Q37156733-2F3C2CE9-48BC-4F7A-BC42-BB1F0243A670Q37248425-827A147D-E855-479E-B147-0ADA115504FEQ37292179-57A54287-BABB-4217-8EED-4C801FCE3BF7Q37476759-9D8DC797-8FA9-451E-9DDE-18587D69B988Q37503262-54C83891-C734-4A9F-B486-8244E1342875Q38881492-34762F91-C16A-4AD6-9FEB-EE02C91763AFQ40159743-85037B72-BF96-4C8F-A9ED-312B1E0D11DBQ40236213-BF175DC2-AAE7-44DE-9FA6-F6D591143505Q41476002-44B18B9F-7715-4CE9-BF6E-76A7B375547DQ47840789-CFA3854D-6A1C-44B6-B340-54B8EA2D3306Q55645023-1B35A364-FA75-4D1F-8C20-8A29CBD219D0
P2860
Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Evaluation of protective effec ...... sma chronic infection in mice.
@en
Evaluation of protective effec ...... ated in monophosphoryl lipid A
@nl
type
label
Evaluation of protective effec ...... sma chronic infection in mice.
@en
Evaluation of protective effec ...... ated in monophosphoryl lipid A
@nl
prefLabel
Evaluation of protective effec ...... sma chronic infection in mice.
@en
Evaluation of protective effec ...... ated in monophosphoryl lipid A
@nl
P2093
P1433
P1476
Evaluation of protective effec ...... sma chronic infection in mice.
@en
P2093
Corinne Mercier
Karine Musset
Majid Golkar
Marie-France Cesbron-Delauw
Mehdi Assmar
Reza Sadaie
P304
P356
10.1016/J.VACCINE.2007.02.057
P407
P577
2007-03-09T00:00:00Z